Who: Cyprium Therapeutics (Fortress Biotech)/Sentynl Therapeutics (Zydus Group)
What: On 24 February, Sentynl signed a development and asset purchase agreement for Cyprium’s CUTX-101, a copper histidinate drug for...
Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.
